Saturation monitoring of VX15/2503, a novel semaphorin 4D-specific antibody, in clinical trials

Cytometry Part B - Clinical Cytometry

Volumn 90, Issue 2, 2016, Pages 199-208

  Fisher, Terrence L ^a   Seils, Jennifer ^a   Reilly, Christine ^a   Litwin, Virginia ^b   Green, Lisa ^b   Salkowitz Bokal, Janelle ^b   Walsh, Robin ^b   Harville, Sarah ^b   Leonard, John E ^a   Smith, Ernest ^a   Zauderer, Maurice ^a  

^a VACCINEX INC   (United States)

^b Labcorp Drug Development   (United States)

Author keywords

clinical trials; receptor occupancy; saturation; Semaphorin4D; VX15 2503

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; SEMAPHORIN; SEMAPHORIN 4D; UNCLASSIFIED DRUG; VX 15; CD100 ANTIGEN; LEUKOCYTE ANTIGEN; VX15-2503 MONOCLONAL ANTIBODY;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MONITORING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; REPRODUCIBILITY; SATURATION MONITORING; SOLID TUMOR; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; FLOW CYTOMETRY; HEALTHY VOLUNTEERS; HUMANS; MULTIPLE SCLEROSIS; SEMAPHORINS;

EID: 84962129076     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21338     Document Type: Article

References (28)

1. Giraudon P, Vincent P, Vuaillat C, Verlaeten O, Cartier L, Marie-Cardine A, Mutin M, Bensussan A, Belin MF, Boumsell. L., Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol 2004; 172: 1246-1255.
2. Giraudon P, Vincent P, Vuaillat. C., Tcells in neuronal injury and repair: Semaphorins and related T-cell signals. Neuromol Med 2005; 7: 207-216.
3. Worzfeld T, Offermanns S., Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov 2014; 13: 603-621.
4. Mendes-da-Cruz DA, Lepelletier Y, Brignier AC, Smaniotto S, Renand A, Milpied P, Dardenne M, Hermine O, Savino W., Neuropilins, semaphorins, and their role in thymocyte development. Ann N Y Acad Sci 2009; 1153: 20-28.
5. Takamatsu H, Takegahara N, Nakagawa Y, Tomura M, Taniguchi M, Friedel RH, Rayburn H, Tessier-Lavigne M, Yoshida Y, Okuno T, et al., Semaphorins guide the entry of dendritic cells into the lymphatics by activating myosin II. Nat Immunol 2010; 11: 594-600.
6. Delaire S, Billard C, Tordjman R, Chedotal A, Elhabazi A, Bensussan A, Boumsell. L., Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J Immunol 2001; 166: 4348-4354.
7. Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfm M, Cardoso AA, Bensussan A, Nadler LM, Freeman. GJ., Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci USA 1996; 93: 11780-11785.
8. Kikutani H, Kumanogoh. A., Semaphorins in interactions between T cells and antigen-presenting cells. Nat Rev Immunol 2003; 3: 159-167.
9. Suzuki K, Kumanogoh A, Kikutani. H., Semaphorins and their receptors in immune cell interactions. Nat Immunol 2008; 9: 17-23.
10. Campos M, Campos SGDE, Ribeiro GG, Eguchi FC, Silva SR, Oliveira CZDE, Costa AMDA, Curcelli EC, Nunes MC, Penna V, et al., Ki-67 and CD100 immunohistochemical expression is associated with local recurrence and poor prognosis in soft tissue sarcomas, respectively. Oncol Lett 2013; 5: 1527-1535.
11. Ch'ng ES, Kumanogoh A., Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer 2010; 9: 251
12. Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F, Ishiguro H, et al., Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer. Cancer Sci. 2011; 102: 2029-2037.
13. Evans EE, Jonason AS, Jr,., Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, et al., Antibody blockade of semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol Res 2015; 3: 689-701.
14. Kumanogoh A, Suzuki K, Ch'ng E, Watanabe C, Marukawa S, Takegahara N, Ishida I, Sato T, Habu S, Yoshida K, et al., Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol 2002; 169: 1175-1181.
15. Okuno T, Nakatsuji Y, Moriya M, Takamatsu H, Nojima S, Takegahara N, Toyofuku T, Nakagawa Y, Kang S, Friedel RH, et al., Roles of Sema4D-Plexin-B1 Interactions in the Central Nervous System for Pathogenesis of Experimental Autoimmune Encephalomyelitis. J Immunol 2010; 184: 1499-1506.
16. Smith ES, Jonason AJ, Reilly C, Veeraraghavan J, Fisher T, Doherty M, Klimatcheva E, Mallow C, Cornelius C, Leonard JE, et al., SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis 2014; 73: 254-268.
17. Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, et al., Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis 2015; 76: 46-56.
18. Nkyimbeng-Takwi E, Chapoval. SP., Biology and function of neuroimmune semaphorins 4A and 4D. Immunol Res 2011; 50: 10-21.
19. Zhang Y, Liu B, Ma Y, Jin. B., Sema 4D/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol 2012; 10: 97-98.
20. Hoffman RA, Wang L, Bigos M, Nolan. JP., NIST/ISAC standardization study: variability in assignment of intensity values to fluorescence standard beads and in cross calibration of standard beads to hard dyed beads. Cytometry A 2012; 81: 785-796.
21. Meinelt E, Reunanen M, Edinger M, Jaimes M, Stall A, Sasaki D, Trotter J., Standardizing application setup across multiple flow cytometers using BD FACVSDiva version 6 software. BD Biosci Techn Bull 2012: 1-16.
22. Westgard JO, Quam EF, Barry PL, Ehrmeyer SS., Basic Method Validation: Training in Analytical Quality Management for Healthcare Laboratories, 2nd ed. Westgard Quality Corporation, Madison, WI, 2003.
23. Litwin V, Andahazy J., Monitoring the Cellular components of the Immune System during Clinical Trials-A translational medicine approach. In:, Litwin V, Marder P, editors. Flow Cytometry in Drug Discovery and Development. New Jersey: Wiley-Blackwell, John Wiley & Sons, Inc.;. 2010.pp 189-204.
24. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, Fourcroy JL, Dixit R, Pandite L, Pietrusko RG, et al., Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005; 22: 499-511.
25. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, Rogers JA, Millham R, et al., Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006; 23: 312-328.
26. O'Hara DM, Xu Y, Liang Z, Reddy MP, Wu DY, Litwin V., Recommendations for the validation of flow cytometric testing during drug development: II assays. J Immunol Methods 2011; 363: 120-134.
27. Nilsson LB., The bioanalytical challenge of determining unbound concentration and protein binding for drugs. Bioanalysis 2013; 5: 3033-3050.
28. Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, Zauderer M., Nonclinical safety evaluation of VX15/2503, a humanized IgG4 anti-SEMA4D antibody. Mol Cancer Ther 2015; 14: 964-972.